Ashkon Software

   







 

BGMD Stock - BG Medicine, Inc.


BGMD Stock Chart

BGMD Profile

BG Medicine, Inc. logo

BGMD (BG Medicine, Inc.) is a healthcare company that focuses on the development and commercialization of diagnostic solutions for patients with cardiovascular and related disorders. The company is headquartered in Waltham, Massachusetts, and operates as a subsidiary of NovoPath, Inc.

BGMD's primary product is the BGM Galectin-3 test, which is a blood test used to identify patients who are at high risk of developing heart failure. The test measures the level of galectin-3, a protein that has been linked to inflammation and fibrosis in the heart, and can provide important information to healthcare providers about a patient's risk of developing heart failure.

BGMD has also developed other diagnostic tests for cardiovascular and related disorders, including tests for kidney disease and liver fibrosis. These tests are designed to provide healthcare providers with important diagnostic information that can help guide treatment decisions and improve patient outcomes.

In terms of financial performance, BGMD has faced some challenges in recent years. The company has reported declining revenues and increasing losses in its financial statements, and its stock price has experienced significant volatility. As of September 2021, the company's market capitalization was around $5 million.

Despite these challenges, BGMD continues to focus on the development and commercialization of innovative diagnostic solutions for patients with cardiovascular and related disorders. The company has a strong intellectual property portfolio and a dedicated team of researchers and developers, and it may be well-positioned to capitalize on opportunities in the growing market for cardiovascular d



 

 
Copyright © 2000-2024, Ashkon Software LLC
Privacy Policy | Refund Policy | Disclaimer